dc.contributor.author
Jeitler, Michael
dc.contributor.author
Michalsen, Andreas
dc.contributor.author
Frings, Daniela
dc.contributor.author
Hübner, Marisa
dc.contributor.author
Fischer, Moritz
dc.contributor.author
Koppold-Liebscher, Daniela A.
dc.contributor.author
Murthy, Vijay
dc.contributor.author
Kessler, Christian S.
dc.date.accessioned
2021-02-22T12:27:03Z
dc.date.available
2021-02-22T12:27:03Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/29695
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-29437
dc.description.abstract
Medicinal mushrooms are widely used in East Asia for the treatment of various diseases, especially in complementary cancer care. While there is a growing interest in medicinal mushrooms in Western countries and an increasing number of pre-clinical studies indicate distinct anti-cancer and regenerative properties, little is known about their potential relevance for clinical practice. This review aims to provide an overview of the clinical evidence, significance and potential role of medicinal mushrooms in complementary cancer care. Scientific databases for (randomized) controlled clinical trials evaluating whole spectrum formulations of medicinal mushrooms (mushroom powder and mushroom extracts) in cancer patients during and/or after conventional oncological treatment were searched. Eight studies met our inclusion criteria (eight randomized controlled trials, one controlled clinical trial). The medicinal mushrooms investigated were Agaricus sylvaticus (two trials), Agaricus blazei murill (two trials), Antrodia cinnamomea (one trial), Coriolus versicolor (one trial) and Ganoderma lucidum (three trials); all were compared to placebo and administered orally. A variety of cancer entities, outcomes and treatment durations were observed. Study results suggested beneficial effects of medicinal mushrooms, particularly quality of life and reduction of adverse effects of conventional therapies. Also, positive effects on antitumor activity and immunomodulation were reported, e.g., an increased activity of natural killer cells. In addition, results might suggest a longer survival of cancer patients receiving mushroom preparations, although in most studies this was not significant when compared to placebo. Adverse events of treatment with medicinal mushrooms were poorly reported; gastrointestinal reactions and a decrease in platelet cell count occurred in some cases. The methodological quality of most studies was generally unsatisfying and most results were insufficiently reported in several respects. Medicinal mushrooms may have a therapeutic potential for cancer patients during and after conventional oncological care with regards to quality of life, reduction of adverse effects of conventional care and possibly other surrogate parameters like immune function. There is an urgent need to investigate the safety and possible interactions of medicinal mushrooms. High-quality clinical research is warranted in order to clarify the potential of medicinal mushrooms in cancer therapy.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
medicinal mushrooms
en
dc.subject
integrative oncology
en
dc.subject
integrative medicine
en
dc.subject
medicinal fungi
en
dc.subject
complementary medicine
en
dc.subject
Integrative medicine
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
580656
dcterms.bibliographicCitation.doi
10.3389/fphar.2020.580656
dcterms.bibliographicCitation.journaltitle
Frontiers in Pharmacology
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.volume
11
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33424591
dcterms.isPartOf.eissn
1663-9812